A brain proteomic signature of incipient Alzheimer's disease in young APOE ε4 carriers identifies novel drug targets.

Jackson A. Roberts,Vijay R. Varma,Yang An,Sudhir Varma,Julián Candia,Giovanna Fantoni,Vinod Tiwari,Carlos Anerillas,Andrew Williamson,Atsushi Saito,Tina Loeffler,Irene Schilcher,Ruin Moaddel,Mohammed Khadeer,Jacqueline Lovett,Toshiko Tanaka,Olga Pletnikova,Juan C. Troncoso,David A. Bennett,Marilyn S. Albert,Kaiwen Yu,Mingming Niu,Vahram Haroutunian,Bin Zhang,Junmin Peng,Deborah L. Croteau,Susan M. Resnick,Myriam Gorospe,Vilhelm A. Bohr,Luigi Ferrucci,Madhav Thambisetty

A brain proteomic signature of incipient Alzheimer's disease in young APOE ε4 carriers identifies novel drug targets.

2021

Aptamer-based proteomics revealed differentially abundant proteins in Alzheimer’s disease (AD) brains in the Baltimore Longitudinal Study of Aging and Religious Orders Study (mean age, 89 ± 9 years...

Keywords:

Disease
Bioinformatics
Medicine
Drug

Correction
Source
Cite
Save
Machine Reading By IdeaReader

165

References

Citations